So when we're looking at refractory melanoma, that is melanoma refractory to checkpoint blockade or other um therapies, um, obviously there are a number of immunological mechanisms that that might play a role there. Um, and the role of, um, MDSCs, regulatory T cells, um, Other immunologically inhibitory um pathways, um, as a potential target for therapy has become of increased interest, um. mucosal melanoma, um. When we look at the infiltrative cells, certainly we can see effector T cells, but we do see those um regulatory T cells present as well. Um, and so the idea of trying to optimize that balance between activating the effector cells, uh, eliminating those regulatory T cells, I think is, is of interest here. Um, you know, as, as I mentioned before, um, because of the limited treatment options for these patients, uh, with advanced mucosa melanoma, they will frequently go on clinical trials with compelling biology. And One of those trials where a number of patients were um enrolled onto was the trial of a drug called nembaleukin on the artistry one trial. And so this was the dose escalation phase 1/2 trial of Nembaleukin, uh, where, um, as part of this trial there was an expansion cohort of patients with melanoma. And um as part of that melanoma group, there were um 6 patients with mucosal melanoma enrolled. Um, of those 62 of those patients had significant radiographic responses. Uh, and You know, these are patients who have progressed on prior therapies, um, where the, the, um, um. Um, Almost any signal of activity is is something that really should be um considered deeply uh and pursued, and so that ultimately led to a lot of excitement in the field. In terms of investigating mucosa melanoma specifically more um in uh with with this sort of um therapy. Right, can we change that balance, um, Between factor T cells and regulatory T cells, uh, to get an anti-tumor response. And so I think it was the combination of the Preclinical rationale. Uh, combined uh with the albeit small but very real clinical efficacy that we saw in that that first in man trial of this age and that really led to enthusiasm for nevolleukin and mucosal melanoma.
Presenter
